Evotec SE (EVO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Evotec SE (EVO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.08

-0.10 (-2.39%)

At close: Jan 14, 2025, 3:59 PM

4.08

0.12%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	4.05
Market Cap	1.45B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.5
PE Ratio (ttm)	-8.15
Forward PE	n/a
Analyst	Buy

Ask	4.11
Volume	46,585
Avg. Volume (20D)	240,122
Open	4.19
Previous Close	4.18
Day's Range	3.98 - 4.20
52-Week Range	2.85 - 8.39
Beta	undefined

About EVO

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly;...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Feb 5, 2004

Employees 5,007

Stock Exchange NASDAQ

Ticker Symbol EVO

Website https://www.evotec.com

Analyst Forecast

According to 2 analyst ratings, the average rating for EVO stock is "Buy." The 12-month stock price forecast is $5.9, which is an increase of 44.79% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

-16.07%

Evotec shares are trading lower after Halozyme wit... Unlock content with Pro Subscription

2 months ago · Source

+6.67%

Evotec shares are trading higher after Halozyme Therapeutics confirmed a cobmination offer.

News

2 weeks ago · seekingalpha.com

Evotec: Some Recovery Has Come, But Much More Is Expected

Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despi...

1 month ago · reuters.com

Halozyme withdraws $2.1 bln buyout offer for Evotec

Halozyme Therapeutics said on Friday it had withdrawn its proposal to acquire Evotec SE for 2 billion euros ($2.09 billion) after the German drug developer was unwilling to engage in discussions.

1 month ago · youtube.com

Halozyme CEO: Evotec Is Poised for Growth

Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on "Bloomberg Technology.

2 months ago · benzinga.com

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

On Thursday, Halozyme Therapeutics, Inc. HALO submitted a non-binding proposal to Evotec SE EVO to acquire the German company for 11.00 euros per share in cash, implying a fully diluted equity value ...

2 months ago · reuters.com

Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

2 months ago · benzinga.com

Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal

Germany-based Evotec SE EVO is trading on Monday after a report that suggests the company is a takeover target.

2 months ago · seekingalpha.com

Evotec SE (EVO) Q3 2024 Earnings Call Transcript

Evotec SE (NASDAQ:EVO ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Laeti...